Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370714 | 0.94 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL12370736 | 0.91 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1HRH3GAAKDM4E | |
| SCHEMBL12370712 | 0.89 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL9588954 | 0.89 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1HRH3GAAKDM4E | |
| SCHEMBL12370731 | 0.86 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1HRH3GAAKDM4E | |
| SCHEMBL12370726 | 0.85 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1HRH3GAAKDM4E | |
| SCHEMBL12370708 | 0.85 | KDM4E (0.50) | ALDH1A1L3MBTL1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL11325754 | 0.83 | HRH3 (0.52) | ALDH1A1L3MBTL1HRH3GAAKDM4E | |
| SCHEMBL31267769 | 0.82 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1MAOB | |
| SCHEMBL12370724 | 0.81 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1HRH3GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633333-B2 | Nitrileoxide compound | DAIKIN INDUSTRIES, LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20180057450-A1 | NITRILEOXIDE COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180057450-A1 | NITRILEOXIDE COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633333-B2 | Nitrileoxide compound | NR5A2, NR0B2, NR0B1 | ALDH1A1 1839/4885L3MBTL1 3858/4885HRH3 107/4885 |
| US-20180057450-A1 | NITRILEOXIDE COMPOUND | NR5A2, NR0B2, NR0B1 | ALDH1A1 1839/4885L3MBTL1 3858/4885HRH3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.